{"slideshow_credits": null, "snippet": "A federal court in Philadelphia has brought some common sense to a devious tactic used by companies to frustrate efforts to speed the advent of generic drugs.", "abstract": "Editorial applauds federal appeals court decision ruling that payments made by brand-name drug companies to generic competitors in order to delay bringing generic drugs to market are an unreasonable restraint of trade; says if decision ever reaches the Supreme Court and is upheld, it will benefit consumers and public and private insurers who are stuck with continuing to pay monopoly prices for brand-name drugs.", "section_name": "Opinion", "print_page": "26", "document_type": "article", "byline": [], "web_url": "http://www.nytimes.com/2012/07/18/opinion/some-legal-clarity-on-generic-drugs.html", "lead_paragraph": "A federal court in Philadelphia has brought some common sense to a devious tactic used by companies to frustrate efforts to speed the advent of generic drugs.", "headline": {"seo": "Some Legal Clarity on Generic Drugs", "main": "Some Legal Clarity on Generic Drugs", "print_headline": "Some Legal Clarity on Generic Drugs", "content_kicker": "Editorial", "kicker": "Editorial"}, "_id": "515d9f5acf28d0219d000c24", "word_count": "433", "multimedia": [], "pub_date": "2012-07-18T00:00:00Z", "source": "The New York Times", "news_desk": "Editorial", "keywords": [{"value": "Decisions and Verdicts", "name": "subject", "is_major": "N", "rank": "1"}, {"value": "Generic Brands and Products", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "3"}, {"value": "Inventions and Patents", "name": "subject", "is_major": "N", "rank": "4"}, {"value": "Courts and the Judiciary", "name": "subject", "is_major": "N", "rank": "5"}, {"value": "Editorials", "name": "subject", "is_major": "Y", "rank": "6"}], "blog": [], "subsection_name": null, "type_of_material": "Editorial"}